Zola confirms Chelsea watching Bournemouth striker Wilsonby Freddie Taylor10 months agoSend to a friendShare the loveGianfranco Zola has confirmed Chelsea’s interest in Callum Wilson.The Bournemouth striker has scored nine goals across all competitions this season, with reports stating the Blues were contemplating a move for the 26-year-old.And speaking before Chelsea take on Bournemouth in the EFL Cup quarterfinal, Zola said the club were interested in the England international.”I’m sure that there are a lot of players that are linked with us,” the Blues assistant said.”Certainly Callum Wilson is doing very well for his club and he is of interest, not just for us, but for many.”He’s strong, fast, and he sees the goal. I like him because he’s quick, but also strong in the air, which is a very important quality.”But I don’t want to go too much into it. He’s doing very well. I’m pleased for him. He has a lot of qualities that can take him a long way.” TagsTransfersAbout the authorFreddie TaylorShare the loveHave your say
About the authorAnsser SadiqShare the loveHave your say Tottenham star Alli makes drastic changes to forget injury woesby Ansser Sadiq16 days agoSend to a friendShare the loveTottenham star Dele Alli is willing to do anything in a bid to end his injury woes.The attacking midfielder has suffered a series of problems in the past 18 months, especially with his hamstrings.The England star is reportedly taking up yoga and seeing a nutritionist to discover what could be causing the problems.The 23-year-old is said to prefer a high protein and low sugar diet to limit inflammation in his body, per the Daily Mail.Alli has the present international break to get back to match fitness, so that he can help Spurs halt a miserable run of results.The midfielder wants to win back his place in the team and cement himself as one of their top performers.
WILMINGTON, MA — Below is a recent announcement from the Wilmington Recreation Department:Dance Classes For AdultsHave you stayed true to your New Year’s healthy lifestyle resolutions? If not, the Wilmington Rec. Department is offering two dance classes for adults that are sure to get you moving and grooving your way to a healthier you.The “Dance Sampler” class introduces you to jazz, ballet, hip hop and lyrical dance lessons. These lessons are offered on Mondays, January 28 – March 11 (no 2/18) from 8 – 9 p.m. Cost is $52.00.Or, try “Tap Dancing” – a class that is designed for both Beginning and Intermediate dancers. In this class, you’ll learn basic tap steps and fun combinations in a light-hearted atmosphere. Classes are held on Thursdays, January 24 – March 7 (no 2/21), 7:30 – 8:30 p.m. Cost is $52.00, tap shoes are required.To register, visit http://www.wilmingtonma.gov/recreation, call 978-658-4270, or stop by Town Hall, Room 8. The Department is open Monday – Friday, 8:30 a.m. – 4:30 p.m.Like Wilmington Apple on Facebook. Follow Wilmington Apple on Twitter. Follow Wilmington Apple on Instagram. Subscribe to Wilmington Apple’s daily email newsletter HERE. Got a comment, question, photo, press release, or news tip? Email email@example.com.Share this:TwitterFacebookLike this:Like Loading… RelatedWILMINGTON REC REMINDERS: Adult Dance Classes Starting Soon; ‘Disney On Ice’ Tickets Sale Ends FRIDAYIn “Community”WILMINGTON REC REMINDERS: Adult Tap Dance Classes, Kids Ballet LessonsIn “Community”Wilmington Recreation Has Discounted Tickets To Canobie Lake Park’s ScreeemfestIn “Community”
Howrah(WB): Two class 5 students drowned in a pond in West Bengal’s Howrah district Tuesday, police said. The two students drowned in a pond in Domjur area of the district while taking a bath, they said.
June 22, 2017 Opinions expressed by Entrepreneur contributors are their own. Free Workshop | August 28: Get Better Engagement and Build Trust With Customers Now Enroll Now for Free 5 min read Morgan Stanley’s recent decision to partner 16,000 financial advisers with algorithms that can identify trades and prod brokers to reach out to clients is evidence of yet another in-road being made by machines into human roles. If brokers embrace this mind-and-machine partnership though, the payoff is job security in an industry in which returns are paramount.The financial services industry is highly Darwinian in nature, with its culture of “survival of the best performers.” Now, bringing artificial intelligence (AI) into the mix is turning the competition up a notch. The most vulnerable, ironically, could be the high-performing brokers who might be tempted to continue alone without algorithmic assistance. But as we’ve seen in chess championships like Garry Kasparov vs. Deep Blue, the supercomputer of its time, or IBM’s Watson’s victory on Jeopardy!, when human and computer are pitted against each other, the computer wins.Related: Good, Bad & Ugly! Artificial Intelligence for Humans is All of This & MoreAs research has shown, however, a human-and-computer collaboration makes an unbeatable combination. That’s why in business, science or other fields, people’s greatest collaborators are likely to be machines. On Wall Street, if a mediocre broker quickly adopts to using a machine as a partner, he or she will become a formidable performer with increased job security, potentially outperforming the strong broker who refuses to leverage the machine.Morgan Stanley, one of the world’s biggest brokerages, will roll out its AI pilot to 500 advisers in July. The rest of its brokers will be involved by year-end. The project is being billed as an augmentation of human brokers, not a robo replacement of them.Automated wealth-management services, known as “robo-advisors,” are already becoming commonplace among many cost-conscious retail investors, who are gravitating toward computers for inexpensive asset allocation and investment advice. A study in Europe by Fujitsu found that 20 percent of respondents said they would buy banking or insurance services from the likes of Google, Amazon or Facebook. Uber has made a step toward financial services by partnering with GoBank to offer checking accounts and debit cards to drivers.Related: Why Small Businesses Should Be Paying Attention to Artificial IntelligenceFor these digital disruptors, their mastery of machine learning would make it relatively easy for them to enter finance — arguably far more easily than financial advisers could enter the field of machine learning. This same problem confronted Wall Street in the 1980s when computers first entered the business. At that time, computer scientists grasped the fundamentals of finance with greater ease than finance experts learned the fundamentals of computer programming. By bringing together expertise in each field — those who know algorithms and those who finance — Wall Street can offer a high-powered collaboration.While traditional brokerage services are seen as susceptible to an “Uber-like” disruption, particularly on the retail end, the high net-worth clientele segment is more likely to be protected — at least for now due to the importance of relationships.Yet even here, the mind-and-machine partnership can take the higher end to another level. Algorithms will send brokers multiple-choice recommendations based on market changes or events in a client’s life, with the objective of generating more business with customers. But humans are being augmented, not replaced. Bloomberg quoted Jeff McMillan, chief analytics and data officer for Morgan Stanley’s wealth-management division, as saying brokers will be needed for the foreseeable future to advise wealthy clients with complicated financial planning needs.It’s analogous to what we see happening in medicine, where AI is being used to enhance physicians’ clinical knowledge in making diagnoses. One can easily imagine the day when individuals will wear biosensors that produce reams of data that can only be digested by computers to help doctors manage patients’ health conditions, from diabetes to allergies.On Wall Street, a machine may excel at making accurate market predictions, but it does so in a “black box” — a very dark and unknowable pool for high net worth investors, in particular. These individuals are used to the high-trust relationships such as in private equity, in which there is a premium for explaining how an investment strategy is structured and is expected to perform. Even the most accurate black box is not likely win the trust of a high-touch client who relies on a human relationship.Thus, for Wall Street’s biggest brokerages such as Morgan Stanley, AI becomes a tool for wealth management. While robo-advisors are embraced by retail investors, high net worth clients who are used to high touch service will still need the human part of the mind-and-machine collaboration. For this clientele, it’s a matter of trust.Related: Can Artificial Intelligence Identify Pictures Better than Humans?But as Morgan Stanley and other Wall Street firms embrace more AI, trust in wealth advisement is likely to become a triangulated relationship. Not only must the two humans — the client and the adviser — trust each other, but the two humans (and especially the adviser) must also trust the machine.For the machine, it’s about using data and machine learning to make market predictions and identify trade opportunities. For the human, it’s about relationships and building trust, an area of expertise in which people still have considerable edge over computers. This hands-on workshop will give you the tools to authentically connect with an increasingly skeptical online audience.
Polish satellite pay TV operator ‘n’ has launched an OTT service. The service – nVOD NET – will give ‘n’ subscribers access to thousands of additional TV series and movies; it launched on November 28.The platform will include Hollywood films, series and documentaries as well as video-on-demand libraries from Polish broadcaster TVN and US premium broadcaster HBO. It will initially be available to around 50% of the company’s subscribers by connecting their decoder to the internet via cable or WiFi and will be free until the end of February 2012.Christian Anting, vice-president and chief operating officer of ‘n’, said: “Today’s news continues our strategy of providing our customers with the best premium content and latest technology innovations. With the launch of nVOD NET, ‘n’ will give subscribers the ultimate in-home movie viewing experience, taking video functionality to a whole new level. We are able to offer access to the best content from leading television producers like TVN and HBO, as well as local and thematic programme offerings via broadband connection.”
Bloodwork was supposed to be the last step in Isela’s application for life insurance. But when she arrived at the lab, her appointment had been canceled.”That was my first warning,” Isela says. She contacted her insurance agent and was told her application was denied because something on her medication list indicated that Isela uses drugs. Isela, a registered nurse who works in an addiction treatment program at Boston Medical Center, scanned her med list. It showed a prescription for the opioid-reversal drug naloxone — brand name Narcan.”But I’m a nurse, I use it to help people,” Isela remembers telling her agent. “If there is an overdose, I could save their life.”That’s a message public health leaders aim to spread far and wide. “BE PREPARED. GET NALOXONE. SAVE A LIFE,” was the message at the top of a summary advisory from the U.S. surgeon general in April.But some life insurers consider the use of prescription drugs when reviewing policy applicants. And it can be difficult, some say, to tell the difference between someone who carries naloxone to save others and someone who carries naloxone because they are at risk for an overdose.Primerica is the insurer Isela says turned her down. (NPR has agreed to use just Isela’s first name because she is worried about how this story might affect her ongoing ability to get life insurance.) The company says it can’t discuss individual cases. But in a prepared statement, Primerica notes that naloxone has become increasingly available over the counter.”Now, if a life insurance applicant has a prescription for naloxone, we request more information about its intended use as part of our underwriting process,” says Keith Hancock, the vice president for corporate communications. “Primerica is supportive of efforts to help turn the tide on the national opioid epidemic.”After Primerica turned her down, Isela applied to a second life insurer and was again denied coverage. But the second company told her it might reconsider if she obtained a letter from her doctor explaining why she needs naloxone. So, Isela did contact her primary care physician — and then realized that her doctor had not prescribed the drug.Isela had bought naloxone at a pharmacy. To help reduce overdose deaths, Massachusetts and many other states have established a standing order for naloxone — one prescription that works for everybody. Isela couldn’t just give her insurer that statewide prescription; she had to find the doctor who signed it. As it happens, that physician — Dr. Alex Walley — also works at Boston Medical Center.Walley is an associate professor of medicine at Boston University; he also works in addiction medicine at Boston Medical Center and is the medical director for the Opioid Overdose Prevention Pilot Program at the Massachusetts Department of Public Health.”We want naloxone to be available to a wide group of people — people who have an opioid use disorder themselves, but also [those in] their social networks and other people in a position to rescue them,” Walley says.He says he’s written a half dozen letters for other BMC employees denied life or disability insurance because of naloxone, and that troubles him.”My biggest concern is that people will be discouraged by this from going to get a naloxone rescue kit at the pharmacy,” Walley says. “So this has been frustrating.”The life insurance hassle — and threat of being turned to down — has discouraged Isela and some of her fellow nurses. She is not carrying a naloxone kit outside the hospital right now because she doesn’t want it to show up on her active medication list until the life insurance problem is sorted out.”So if something were to happen on the street, I don’t have one — just because I didn’t want another conflict,” Isela said.BMC has alerted the state’s Division of Insurance, which has said in a written response that it is reviewing the cases and drafting guidelines for “the reasonable use of drug history information in determining whether to issue a life insurance policy.”But Isela isn’t a drug user. And yet, she is being penalized as if she were.Michael Botticelli, who runs the Grayken Center for Addiction Medicine at BMC, says friends and family members of patients with an addiction must be able to carry naloxone without fear that doing so will send them to the insurance reject pile.”It’s incumbent on all of us to make sure that we try to kind of nip this in the bud,” he says, “before it is any more wide-scale.”Botticelli says increased access to naloxone across Massachusetts is one of the main reasons overdose deaths are down in the state. The most recent state report shows 20 fewer fatalities this year compared to last.Botticelli relayed his concerns in a letter to Dr. Jerome Adams, the U.S. surgeon general, who says he contacted the National Association of Insurance Commissioners. That group says it has not heard of any cases of life insurance applicants being denied because they purchased naloxone.Adams says it’s good to, as Botticelli suggests, nip the problem in the bud.”Naloxone saves lives,” Adams says, “and it is important that all Americans know about the vital role bystanders can play in preventing opioid overdose deaths when equipped with this lifesaving medication.”Isela says the second company that rejected her has agreed to let her reapply, in light of Walley’s letter stating that she carries the drug so that she can reverse an overdose. Isela is in the process of reapplying.This story is part of a reporting partnership with NPR, WBUR and Kaiser Health News. Copyright 2018 WBUR. To see more, visit WBUR.
Get 1 Year of Green Entrepreneur for $19.99 Cannabis Journalist | Tech Evangelist Covering High Growth Trends 8 min read Next Article Image credit: Kevork Djansezian | Getty Images Add to Queue Guest Writer Andre Bourque Green Entrepreneur provides how-to guides, ideas and expert insights for entrepreneurs looking to start and grow a cannabis business. People growing their own marijuana is a significant concern to Big Pharma. As state legalization of cannabis-derivatives spreads, the drug companies contemplating the potential of medical marijuana see a threat from both homegrown and professionally harvested medical-grade marijuana.Pharma offers quality control and deep testing but experience shows that research and development adds to customer cost. Even the 21st Century Cures Act won’t speed up the famously slow pace of FDA drug approvals. Given the facts and the perception, you have to wonder if Big Pharma is for or against legalizing marijuana.Related: Science and FDA Say Cannabis Is Medicine but DEA Insists It Isn’tHere’s the problem.A lot of money always attracts a lot interest. Big Pharma wants the revenues that marijuana promises but concede market forces threaten their interests. Big Pharma can’t getting its biggest slice of the pie with individuals and licensed producers harvesting cannabis, not to mention the the black market that continues to thrive.Ben Cohen, writing for US News, insists it’s all about money. He writes, “For years, large corporations and well-heeled lobbyists have blocked the legalization of marijuana for medical use or recreational use in order to protect their own profits.”There’s no reason to expect this to stop.On the other hand, cannabis advocates have a personal and emotional investment in promoting the legalization, or at least decriminalization, of marijuana. Sometimes that makes them anti-institutional and they skew the role of Big Pharma. Finding an objective point of view is difficult.You might consider the hypocrisy at the February 2014 meeting of the Community Anti-Drug Coalition of America (CADCA). While speaker after speaker preached against the legalization of marijuana, leading financial sponsors of the program included Purdue Pharma, the manufacturer of Oxycontin.As reported in The Nation, both CADCA and the Partnership for Drug-Free Kids (formerly the Partnership for a Drug-Free America) accept financial support from the producers of the same opioid medications that have led to tens of thousands of deaths. The same two groups, among others, have opposed U.S. Congressional efforts to label prescription opioids for “severe pain,” but they have supported continuing Medicare reimbursement for the addictive pills.Moreover, pharmaceutical companies take shelter in the DEA’s listing of marijuana as a Schedule 1 drug, the same category as heroin. As long as the DEA effectively prohibits marijuana medical research, Big Pharma can take the moral high road. The Schedule 1 designation severely limits needed research into the medical efficacy of cannabis-derivatives.”Big pharma is lobbying against legalization, on the purported grounds of safety, but in reality, they are just buying time to create their own synthetic cannabis medicines,” said Alan Hirsch, CEO of Diagnostic Lab Corporation, a cannabis safety and science company. “Several biotech companies have started creating cannabinoid chemistry from rice or yeast, but eventually, these medicines will be manufactured by Big Pharma in Schedule 1 facilities.” Big Pharma Is Developing Cannabis Painkillers – Here’s What They Can Do To Become Part of the Mainstream Market. https://t.co/WGj1yWE2rv pic.twitter.com/s0w3fmzsPe— HIGH TIMES (@HIGH_TIMES_Mag) July 19, 2017 The problem that started with the Trump campaign.Many of the same voters who elected President Donald J. Trump voted to liberalize marijuana enforcement. And, like everything else with the arrival of the Trump administration, things remain in a state of confusion pending official updated stance.In a Town Hall (03/20/2016) meeting, then-candidate Trump said, “I think that as far as drug legalization we talk about marijuana and in terms of medical I think I am basically for that. I’ve heard some wonderful things in terms of medical. I’m watching Colorado very carefully to see what’s happening out there.”Related: Getting Healthy, Not High: Using Cannabis to Fight CancerOn The O’Reilly Factor (02/12/2016), when Fox News’ Bill O’Reilly called medical marijuana a “ruse,” candidate Trump said, “But I know people that have serious problems and they did that they really — it really does help them.”Later, candidate Trump told the Washington Post (10/29/2016), “In terms of marijuana and legalization, I think that should be a state issue, state-by-state … Marijuana is such a big thing. I think medical should happen — right? Don’t we agree? I think so. And then I really believe we should leave it up to the states.”Decades ago he also told the Miami Herald (04/14/1990) “We’re losing badly the War on Drugs. You have to legalize drugs to win that war. You have to take the profit away from these drug czars.”Confusion about the Trump Administration and cannabis.President Donald J. Trump has sent several confusing signals to the pharmaceutical industry and the cannabis advocates. NewsMaxFinance (03/03/3017) quoted President-elect Trump as saying, “pharmaceutical companies are ‘getting away with murder’ in what they charge the government for medicines.” President Trump repeated that charge at a press conference reported by the Washington Post (01/11/2017) when he also said, “Pharma has a lot of lobbies, a lot of lobbyists and a lot of power.”Fox Business (02/01/2017) interviewed Eli Lilly’s CEO David A. Ricks following Trump’s White House meeting with pharmaceutical industry leaders. “When asked if he gave the president any commitment to reducing drug prices or to investing in U.S. operations or jobs, Ricks responded, ‘No, Lilly didn’t do that. But, what we did say is that with the right policy environment, in particular, the corporate tax rate which today is an inhibitor for us to invest in manufacturing here in the United States, along with other pro-business policies could allow us to expand operations in the U.S’.”Related: Will the ‘Entrepreneur’ President Embrace the Cannabis Economy?And, Emma Court of MarketWatch (03/01/2017) reported following Trump’s first State of the Union Address, “The Tuesday evening mention of drug prices underscores ‘our view that Trump is committed to some action to permit federal government involvement in pricing under Medicare Part D, his position for a year,’ Evercore ISI policy analyst Terry Haines said. ‘We continue to think that comes during ACA reform legislation when Trump can insist something be included as a condition of him signing the bill into law.’”So perhaps President Trump is jawboning the pharmaceutical industry to make a deal? Trump wants some concession he can take to his populist constituency in trade for lower corporate taxes. On the surface, this has nothing to do with marijuana. In fact, his position on marijuana may be something he can trade.Related: Marijuana Advocates Wait for Trump’s Stance on Legalized CannabisIt’s all about the money.Is Big Pharma for or against legalizing marijuana? Nothing shows that they favor accessibility to marijuana, and everything points to their opposition. However, investors in Big Pharmacy see the light. They remain in the market and are buying up. They see that there’s no moral high road here but there is money for Big Pharma in cannabis.“No pharmacy company is interested in making cheaper medicine,” Brian Chaplin, founder of Medicine Box told me in a written interview. “The existing Pharma industry is more about patenting and manufacturing medicine that is a treatment plan – not a curative plan.”Chaplin argues that Big Pharma wants customers to need their products, preferably for the rest of their lives, while creating “customers” but not healing specific ailments.“This is different from a ‘whole plant’ medicine approach — where we see patients responding to the synergistic effects of multiple compounds (cannabanoids and terpenes) in the plant that are usually lacking in a pharmacy — chemically prepared product,” he continued. Interestingly, Big Pharma playing in the fields of cannabis might, in fact, help declassify the plant. Christopher Teague of HERB writes, “Big Pharma will prove that cannabis is medicine a hundred times over, in every way, and the DEA will have to reclassify the plant itself.”According to Matt Gray, CEO and founder of HERB, “Big Pharma has already dipped its toe into cannabis treatment, with the DEA approving synthetic cannabis for pharma company, Insys.”That same company, however, also donated money to prevent cannabis legalization from occurring in Arizona. “This just proves the point that Big Pharma cares more about their bottom line than the actual treatment of patients,” he continued. “So if they find it financially beneficial, they will get involved in the industry, even if it isn’t necessarily for the right reasons.”In the end, it’s all about striking a winning balance. Trump needs a victory over high drug prices, especially as they affect Medicare Part D. Big Pharma is in a position to demand concessions. Accessibility to cannabis R&D might just be one of them. Pharmaceutical companies are intrigued by the immense and growing medical marijuana market but cannot figure a way to corner it. Cannabis August 8, 2017 –shares Opinions expressed by Entrepreneur contributors are their own. Is Big Pharma for or Against Legalizing Medical Marijuana? Maybe Both. Subscribe Now
Social Media Reporter Next Article Guest Writer Michael Kan Free Webinar | July 31: Secrets to Running a Successful Family Business 2 min read Image credit: JaysonPhotography / Shutterstock.com Learn how to successfully navigate family business dynamics and build businesses that excel. Russian efforts to influence American society over social media may have reached more than half of the country’s voting population, according to new findings that’ll be presented to Congress today.Facebook, for instance, has found that 126 million users in the country may have been exposed to 80,000 divisive political posts written by a Kremlin-back Russian company, according to The New York Times.Twitter uncovered over 36,000 accounts possibly linked with Russia that generated 1.4 million automated election-related tweets, according to a source familiar with its upcoming testimony. Those tweets received 288 million impressions.Google, on the other hand, found 1,108 videos on YouTube probably associated with a suspected Russian campaign to spread propaganda. The videos attracted 309,000 views in the U.S.More details will be presented during today’s congressional hearing on Russian interference in last year’s election. Representatives from all three U.S. tech companies are set to testify.Facebook will reportedly disclose that a Russian company called the Internet Research Agency controlled 470 accounts to publish the 80,000 posts. Those posts were served directly to 29 million users, and then liked, shared or followed by others, magnifying their spread.Russia’s Internet Research Agency, which is notorious for being an Internet troll farm, also spent $100,000 to display 3,000 ads on the platform with divisive political and social messages, Facebook claimed last month.Twitter also tracked over 2,700 users accounts to the Russian company, up from the 201 accounts it initially reported last month. All the accounts have been suspended. In addition, Twitter identified over 36,000 accounts found generating automated election-related content that possessed “at least one characteristic” associated with Russian user accounts.Although the accounts produced 1.4 million tweets, that only represented 0.74 percent of overall election-related tweets during the Sept. 1 to Nov. 15 time period, according to Twitter’s upcoming testimony.Despite Facebook’s and Twitter’s attempts to crack down on the abuse, U.S. lawmakers remain concerned that foreign governments will try to spread propaganda over their platforms in future elections. That may put Silicon Valley and Washington at odds over attempts to regulate social media.However, both Facebook and Twitter are taking steps to add more transparency to their online political ad business, including who buys what. Last week, Twitter banned two Russian media groups from advertising on the platform over concerns they were spreading Kremlin-back propaganda. Facebook, Google and Twitter are set to testify before a congressional subcommittee on Russia’s attempt to use social media to influence last year’s election. Facebook Says 126 Million Users May Have Been Exposed to Russian Posts –shares October 31, 2017 Add to Queue This story originally appeared on PCMag Register Now »
Add to Queue –shares Be inclusive, be respectful, and beware of the after party. Holidays December 11, 2017 Guest Writer Image credit: Ulrik Tofte | Getty Images Jonathan Segal Partner in Employment Practice Group of Duane Morris 8 Ways to Increase Holiday Cheers and Minimize January Jeers Next Article Apply Now » Opinions expressed by Entrepreneur contributors are their own. The holiday season can be the most wonderful time of the year, but it also poses legal and employee relations challenges to employers of all sizes. Most of these challenges can be mitigated with some thoughtful planning. So, here’s a checklist of some of the more salient issues to consider to minimize the risk that your December celebrations will result in January claims.1. Don’t eliminate Christmas.Don’t eliminate Christmas from the holiday season, says this Jewish guy. It’s a beautiful holiday that should be celebrated. And, a Christmas tree is just fine, too! Remember, it’s about inclusion, not exclusion. So, speaking of inclusion — what about those who don’t celebrate Christmas?Related: 6 Strategic Ways to Prepare Your Small Business for the Festive Season2. Include other holidays.Recognize other holidays, such as Hanukkah and Kwanza, in your decorations and announcements. For example, consider a menorah and Kwanza basket along with the Christmas tree. 3. What holiday did you forget?You don’t know what you don’t know. Profound, no? So, ask. Ask employees if there is a holiday that they would like to see included in the celebration (and that includes decorations). Reminder: the Buddhist holiday of Bodhi day falls on January 5 this year. 4. What should you call your party?“Holiday party” or “Celebration of the Season” are inclusive terms. Make the party itself inclusive too by having decorations and the music reflect diverse holidays. But which decorations and songs? Those that are more religious are more appropriate for religious celebrations (or for religious employers). Fact: Springsteen’s “Santa Claus is Coming to Town” is just fine!Related: 4 Ways to Prepare Your Marketing for the Upcoming Holiday Season5. Should you serve alcohol?Never serve it to minors. Make clear adults who get it for them will be subject to immediate discharge. As for adults, take steps to minimize abuse, such as limiting drinks, providing lots of food or even making employees pay for alcohol and then donating the money, with a match, to charity.Even with restrictions, assume some people may abuse the alcohol you serve. Consider having cab vouchers ready for them without management knowing who the users are. This increases the likelihood that those who need vouchers will use them.6. What about harassment?This is perennial problem at holiday parties. But you can bet this year employees who are subject to improper conduct appropriately will speak up. #MeToo. Remind your employees that your anti-harassment policy applies to the party. But that’s not enough. Make sure to remind managers of their responsibilities. If you are in management and you see or hear unacceptable comments or conduct, you must intervene. To see and ignore is to condone.7. What about the “after party?”To be blunt, no good comes from after parties. Unless, you consider claims arising out of the after party good. Make clear you are not sponsoring any after party, and do not allow employer money to be used for it. And, never attend if you are in management. Attending is about as safe as walking on railroad tracks.Related: Don’t Commit These 7 Party Fouls Inspired by ‘Office Christmas Party’8. What about greetings?It’s best to be general with your holiday greetings unless you know otherwise. The default should be “Happy Holidays.” But if you know someone is Christian, by all means wish that person a Merry Christmas. I do, and I appreciate it when people wish me a “Happy Hanukkah” because they know I am Jewish. I am less thrilled if they are making assumptions. When addressing groups, be as inclusive as you can be, as I shall try to do now: If you celebrate Christmas, Hanukkah or Kwanzaa, I wish you a peaceful and meaningful holiday that corresponds with your faith. If you observe another holiday now, I apologize for not referencing it by name, but I give you my good wishes just the same, as I do for those who recognize no holidays or who celebrate at another time of year. May peace be with all! And, please, be good to each other. 4 min read The only list that measures privately-held company performance across multiple dimensions—not just revenue. 2019 Entrepreneur 360 List
Add to Queue March 19, 2018 Apple Is Reportedly Trying to Make its Own Displays Next Article –shares 2 min read Matthew Humphries Image credit: via PC Mag Senior Editor Apple’s laptops, smartphones, tablets and watches rely on hundreds of parts, most of which Apple sources from other companies around the world. But the more of those parts Apple can make itself, the more profit it can generate as well as making its supply chain more reliable. Apple already started making its own chips, now it’s attempting to make displays.As Bloomberg reports, Apple is thought to be designing and producing its own displays in a secret manufacturing facility near California. More specifically, the focus is on producing MicroLED screens like those recently produced by Samsung to form the 146-inch modular TV launching in August.In Apple’s case, perfecting MicroLED screen production would remove the need to rely on companies including Samsung, Japan Display, Sharp, and LG Display. We could see Apple displays used in the Apple Watch ($329.00 at Best Buy), iPhone, iPad and maybe even MacBooks ($1,249.00 at Amazon) in the future, but there’s one big problem: MicroLED is extremely difficult to manufacture.Apple’s focus on MicroLED is due to the benefits offered, notably they create thinner, brighter and less power-hungry displays without the downsides of OLED (limited life span, brightness). However, because each pixel has its own light in a MicroLED array, it throws up some manufacturing challenges. Those challenges apparently almost made Apple shut down the project last year, but it didn’t, and now working displays are being produced.It’s unlikely we’ll see these Apple displays any time soon, if at all. The cost of mass producing OLED and eventually MicroLED will continue to fall and other manufacturers already focused on display production will benefit first. Apple would need to invest heavily in facilities before it could get serious about making displays. So, for the foreseeable future, expect Apple to continue signing display contracts with its partners. Free Webinar | July 31: Secrets to Running a Successful Family Business This story originally appeared on PCMag Apple If successful, Apple will no longer have to rely on another company for its screens. Learn how to successfully navigate family business dynamics and build businesses that excel. Register Now »
Lindsay Friedman Are You in the Top 50 Percent of Earners in Your City? — Start Up Your Day Roundup Next Article Staff writer. Frequently covers franchise news and food trends. Register Now » 2 min read Free Webinar | July 31: Secrets to Running a Successful Family Business Opinions expressed by Entrepreneur contributors are their own. Add to Queue March 10, 2016 Learn how to successfully navigate family business dynamics and build businesses that excel. Start Up Your Day Image credit: Shutterstock Everyone can give you the headlines. We help you learn from the day’s shifts, both big and small. McDonald’s opens in Borat’s home country. The Big Mac comes to Kazakhstan, according to the New York Post. The fast food franchise opened its first location in the country on Tuesday.The tipping point. Looking at the amount of money it takes to make it into the top 1 or 10 percent of earners can be downright dispiriting. But cracking the top 50 percent? That’s not as discouraging! In New York City, for example, if you make $52,000 a year you’re earning more than 50 percent of residents, according to Business Insider.Just like in the movies. Goodyear unveiled spherical tires, similar to the ones seen in the Will Smith movie I, Robot, at the Geneva International Motor Show. While the tires are still a concept, they’re pretty cool to look at. Venture Beat has more.Watch a Google smart car hit a bus. The very slow, very anti-climactic video is finally out and ready for you to see.Lost and out of network on the road? Try out this new GPS application, which stores maps on your smartphone for offline use. It now covers the entire globe, save for a couple of volcanic islands and Antarctica. –shares
CognitiveScale Expands Relationship with Microsoft through Deeper Product Integration PRNewswireJune 5, 2019, 10:28 pmJune 5, 2019 CognitiveScale Cortex now live on Microsoft Azure MarketplaceCognitiveScale Inc., an Enterprise AI software pioneer, has expanded its strategic relationship with Microsoft to further accelerate adoption of CognitiveScale’s Cortex software amongst businesses using Microsoft Azure.Today, enterprises spend weeks deploying AI platforms and building intelligent business processes in their cloud or data center environments. As a result, AI projects take a long time to get started and deliver value. Built on open and extensible specifications, Cortex simplifies the design, development, delivery and management of cognitive business processes that get smarter and better with time. In recent tests, Cortex successfully reduced AI build time by 65% and overall AI DevOps time by 94% through its unique virtualization technology.With CognitiveScale Cortex now deeply integrated with Microsoft Azure and available on the Microsoft Azure Marketplace, businesses will be able to quickly deploy the full Cortex product suite in their Azure cloud environment. Cortex software also now integrates seamlessly with a suite of Azure models ranging from Natural Language Processing (NLP) to Computer Vision that can be used by enterprises to speed up their AI system development.Marketing Technology News: IBM Debuts Self-Service AI-Powered Ad Experience to Enable Conversations Between Brands and ConsumersHaving worked together since April 2017 to bring industry specific cognitive systems jointly to the market, the collaboration will enable businesses to quickly and easily deploy the Cortex platform and agents, reducing time and cost of deployment, which are major considerations when adopting AI platforms. The expansion also reaffirms Azure as CognitiveScale’s preferred cloud provider.“Deepening our relationship with Microsoft Azure helps put Cortex at the fingertips of millions of businesses across the globe while giving them the freedom to rapidly develop and deploy trusted AI solutions to solve their unique business challenges,” said Akshay Sabhikhi, CEO of CognitiveScale. “Enterprises on Azure can now seamlessly apply our powerful AI software to transform customer engagement as well as boost employee expertise and operational productivity within a matter of minutes, while keeping control of their most sensitive data within their virtual enterprise.”Ed Fandrey, U.S. Vice President of Financial Services at Microsoft said, “We’re pleased to enable close collaboration between Microsoft and CognitiveScale so customers can more rapidly develop and deploy AI-powered applications with the power of Microsoft Azure, for use cases across financial services, healthcare, digital commerce and other industries.”Marketing Technology News: CHEQ Report: Online Ad Fraud To Cost $23 Billion Globally in 2019Chris Corrado, COO and CIO of London Stock Exchange Group said, “The most successful companies today are relentlessly focused on bringing agility and scale to digital services and applications. We are excited about working with both Microsoft and CognitiveScale to realize our strategy of delivering breakthrough AI innovations that bring efficiency, transformation, and transparency to the financial markets.”At the recent London Tech Week, Akshaya Bhargava, ex-CEO Barclays’ Wealth and Founder and CEO of Bridgeweave, along with CognitiveScale and Microsoft, talked about how AI is transforming the financial services sector. Bridgeweave’s Investment Insightsis a new fintech product that is targeted toward self-directed investors. It has the potential to democratize investing by providing institutional asset management level AI-powered trading insights to individual investors who want to participate in the stock market. The product has been built using CognitiveScale’s Cortex software and runs on Microsoft’s Azure.Marketing Technology News: Instaclustr Anomaly Detection Application Successfully Processes 19 Billion Real-Time Events Per Day Using Apache Cassandra and Apache Kafka AIAkshay SabhikhiCognitiveScaleCortex softwareMarketing Technology NewsMicrosoft AzureNews Previous ArticleExperience Management Leader Medallia to Acquire Behavioral Analytics Startup CooladataNext ArticleNew Total Economic Impact Study Finds Blueshift Delivers 781% Return on Investment (ROI)
Reviewed by Alina Shrourou, B.Sc. (Editor)Oct 4 2018Basis, a company offering an innovative approach to taking care of your mental health, announced today the launch of its new service designed to bring evidence-based support to more people. Basis’ approach is the first of its kind and reduces barriers like cost, hassle and perceived stigma associated with mental health care. The company has raised $3.75 million in funding led by Bedrock, with additional participation from Wave Capital and Lightspeed Venture Partners.According to federal health data, more Americans are experiencing emotional distress than ever. One in five Americans will have a diagnosable psychological disorder in a given year and only 43.5% receive treatment. Of those receiving care, 20% continue to report unmet need and fewer than 10% are receiving care consistent with the best scientific evidence. Additionally, daily stressors such as work-related pressures or relationship conflict often get overlooked and dismissed in an effort to avoid the cost, time and stigma commonly associated with seeking help.Founded by ex-Uber executive Andrew Chapin (CEO) and Stanford psychologist Dr. Lindsay Trent (Chief Science Officer), Basis was created to offer an affordable, convenient alternative to paying hundreds of dollars an hour for a therapist. For just $35/session, clients get same-day access to specialists trained in research-backed approaches to working through life’s tough moments. Basis sessions are designed to fit into your life like a workout class or a phone call with a friend, rather than a visit to the doctor’s office.”After experiencing high levels of stress in previous work environments, I was frustrated with the options for dealing with my day-to-day anxieties,” says co-founder and CEO Andrew Chapin. “While yoga and meditation gave me temporary relief, they didn’t help me work through the issues I faced. The idea of seeing a therapist felt too clinical for my situation; I just needed help dealing with the everyday challenges of being human. While exploring new models for taking care of my mental health, I met Dr. Trent. We realized there was a huge opportunity to provide evidence-based solutions at a drastically lower price point.”Related StoriesIU-connected startup working to enable precision medicine for mental health issues, chronic pain‘Climate grief’: Fears about the planet’s future weigh on Americans’ mental healthParticipation in local food projects may have positive effect on healthStudies have shown that trained but unlicensed paraprofessionals achieve clinical outcomes equal to or better than those obtained by licensed clinicians. Every Basis Specialist completes extensive training developed by Stanford psychologists in research-backed approaches (specifically, motivational interviewing and structured problem solving). Research supports the effectiveness and generalizability of these strategies, making them appropriate for working through everyday life challenges.According to Co-Founder and Chief Science Officer Dr. Lindsay Trent, “There is a vast disconnect between academia and real-world practice that greatly affects the quality of care accessible to most people. Finding a clinician who provides best practices according to research and implements all of the components correctly is incredibly difficult. Over the past decade, my research focused on efforts to bridge the gap between science and practice. Sadly, traditional dissemination strategies produced dismal results, and it became clear that an innovative solution was desperately needed. The Basis model, on the other hand, dramatically reduces cost without sacrificing outcomes. We’re delivering an evidence-based approach in a super convenient experience that actually fits into the lives of people who need it.”It’s easy to begin using Basis: users sign up on the app or website and complete a simple questionnaire so Basis can learn about their needs. Basis will match them with an expertly trained specialist, who will have the context the user shared so they can jump right into the discussion. Sessions are forward looking and practical, and focus on how you can feel and function better despite whatever you’re facing. Every session ends with a concrete takeaway and plan. Clients are able to schedule a session anytime that fits into their schedule as soon as a few hours in advance, and all sessions are confidential and anonymous. Source:https://www.mybasis.com/
Press Trust of India AllahabadJuly 11, 2019UPDATED: July 11, 2019 18:42 IST Bareilly BJP MLA Rajesh Mishra’s daughter Sakshi and her husband Ajitesh on Thursday filed a petition in the Allahabad High Court, seeking protection to “live a peaceful life” as a married couple.The next hearing in the case has been fixed for July 15 as Shakshi Mishra and her husband Ajitesh were not present in the court.Sakshi Misra (23) had uploaded a video on a social media platform last week, making her marriage with Ajitesh Kumar (29) public.In another video, she alleged there was a threat to her life from her father, brother and an associate.The couple asked for security, contending that there was a threat to their life from the BJP MLA, who was “unhappy” with their marriage as Sakshi was a Brahmin and Ajitesh a Dalit.The petitioners prayed that police or Rajesh Mishra do not disturb them in “their peaceful living as both petitioners were major and had entered into marriage with a free will”.ALSO READ | Respect her decision: BJP MLA denies threatening his daughter for marrying DalitALSO WATCH | Watch: Drunk BJP MLA Pranav Singh Champion brandishes guns while dancingFor the latest World Cup news, live scores and fixtures for World Cup 2019, log on to indiatoday.in/sports. Like us on Facebook or follow us on Twitter for World Cup news, scores and updates.Get real-time alerts and all the news on your phone with the all-new India Today app. Download from Post your comment Do You Like This Story? Awesome! Now share the story Too bad. Tell us what you didn’t like in the comments Posted byAnupriya Thakur Tags :Follow BJP MLA Bareilly BJP MLA’s daughter who married Dalit moves court, seeks protectionBareilly BJP MLA Rajesh Mishra’s daughter Sakshi and her husband Ajitesh on Thursday filed a petition in the Allahabad High Court, seeking protection to “live a peaceful life” as a married couple.advertisement Next